share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

诺和诺德 | 6-K：诺和诺德-股票回购计划
美股SEC公告 ·  05/28 06:07

Moomoo AI 已提取核心信息

Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program. Initiated on May 6, 2024, the program is part of a larger 12-month buyback plan, which began on February 6, 2024, with a total budget of up to DKK 20 billion. As of May 27, 2024, Novo Nordisk has repurchased 436,152 B shares under the current program, amounting to DKK 397,178,886. The transactions were made between May 17 and May 24, 2024, with the purchase prices ranging from DKK 906.86 to DKK 937.21 per B share. Overall, since the start of the buyback plan in February, the company has acquired 9,170,402 B shares at an average price of DKK 864.18, totaling DKK 7,924,913,659. These repurchased shares are part of the company's treasury shares, which now total 10,535,966 B shares, representing 0.2% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and has a presence in 80 countries, with its products marketed in approximately 170 countries.
Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program. Initiated on May 6, 2024, the program is part of a larger 12-month buyback plan, which began on February 6, 2024, with a total budget of up to DKK 20 billion. As of May 27, 2024, Novo Nordisk has repurchased 436,152 B shares under the current program, amounting to DKK 397,178,886. The transactions were made between May 17 and May 24, 2024, with the purchase prices ranging from DKK 906.86 to DKK 937.21 per B share. Overall, since the start of the buyback plan in February, the company has acquired 9,170,402 B shares at an average price of DKK 864.18, totaling DKK 7,924,913,659. These repurchased shares are part of the company's treasury shares, which now total 10,535,966 B shares, representing 0.2% of the share capital. Novo Nordisk, established in 1923 and headquartered in Denmark, is committed to combating serious chronic diseases and has a presence in 80 countries, with its products marketed in approximately 170 countries.
全球领先的医疗保健公司诺和诺德A/S宣布了其股票回购计划的进展。该计划于2024年5月6日启动，是更大的12个月回购计划的一部分，该计划于2024年2月6日开始，总预算高达200亿丹麦克朗。截至2024年5月27日，诺和诺德已根据当前计划回购了436,152亿股股票，总额为397,178,886丹麦克朗。这些交易是在2024年5月17日至5月24日之间进行的，收购价格从每B股906.86丹麦克朗到937.21丹麦克朗不等。总体而言，自2月份回购计划启动以来，该公司已收购了9,170,402亿股股票，平均价格为864.18丹麦克朗，总额为7,924,913,659丹麦克朗。这些回购的股份是公司库存股的一部分，目前共有10,535,966股B股，占股本的0.2％。诺和诺德成立于1923年，总部位于丹麦，致力于抗击严重的慢性病，业务遍及80个国家，其产品销往约170个国家。
全球领先的医疗保健公司诺和诺德A/S宣布了其股票回购计划的进展。该计划于2024年5月6日启动，是更大的12个月回购计划的一部分，该计划于2024年2月6日开始，总预算高达200亿丹麦克朗。截至2024年5月27日，诺和诺德已根据当前计划回购了436,152亿股股票，总额为397,178,886丹麦克朗。这些交易是在2024年5月17日至5月24日之间进行的，收购价格从每B股906.86丹麦克朗到937.21丹麦克朗不等。总体而言，自2月份回购计划启动以来，该公司已收购了9,170,402亿股股票，平均价格为864.18丹麦克朗，总额为7,924,913,659丹麦克朗。这些回购的股份是公司库存股的一部分，目前共有10,535,966股B股，占股本的0.2％。诺和诺德成立于1923年，总部位于丹麦，致力于抗击严重的慢性病，业务遍及80个国家，其产品销往约170个国家。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间